Federal Regulators Highlight Recall of Nearly 40,000 Bottles of Clear Eyes Maximum Itchy Eye Relief Drops
Major news organizations and federal regulators continued drawing attention to an active product safety recall involving nearly 40,000 bottles of Clear Eyes Maximum Itchy Eye Relief eye drops, following widespread distribution across major national retail chains. Prestige Brand Holdings, based in Tarrytown, New York, voluntarily initiated the removal of 39,060 bottles due to a lack of assurance of sterility and potential contamination concerns.
The United States Food and Drug Administration (FDA) classified the action as a Class II recall. This classification indicates that the use of, or exposure to, the affected product may cause temporary or medically reversible adverse health consequences, while the probability of serious long-term harm remains remote. As of reporting updates, public health authorities have confirmed that no injuries or adverse medical events have been reported in connection with the recalled bottles.
Recall Specifications and Distribution
The recalled merchandise was distributed nationwide through Medtech Products, Inc., a subsidiary of Prestige Consumer Healthcare. Major retailers that carried the product include Walmart, Kroger, Target, Dollar General, and Family Dollar.
Consumers who purchased the eye drops are advised to check their medicine cabinets against the specific product identifiers provided by federal health authorities:
- Product Name: Clear Eyes Maximum Itchy Eye Relief eye drops
- Bottle Size: 15 milliliters
- Lot Code: 2552A
- Expiration Date: September 30, 2027
- Company: Prestige Brand Holdings / Prestige Consumer Healthcare
Consumer Guidance
Public health officials recommend that consumers stop using the affected eye drops immediately. Customers possessing the specific lot can return the product to the original place of purchase for a full refund. Additional inquiries regarding the recall can be directed to the manufacturer's customer service channels.
The recall initially commenced when quality assurance reviews flagged sterility issues during routine evaluations, prompting coordinated oversight by regulatory bodies to remove the impacted inventory from consumer access.
Comments (0)
No comments yet. Be the first to share your thoughts!